Lisa Seitz

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

Hong Xiao, Daniel J. Dairaghi, Jay P. Powers et al. · Journal of the American Society of Nephrology · 2013 · 356 citations

Life Sciences, Immunology, Pathobiology +17

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Pirow Bekker, Daniel J. Dairaghi, Lisa Seitz et al. · PLoS ONE · 2016 · 150 citations · Full text

Life Sciences, Immunology, Pharmacology +17

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

Timothy J. Sullivan, Zhenhua Miao, Daniel J. Dairaghi et al. · American Journal of Physiology-Renal Physiology · 2013 · 88 citations · Full text

Medicine, Endocrinology, Pharmacology +17

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

Daniel J. Dairaghi, Babatunde O. Oyajobi, Anjana Gupta et al. · Blood · 2012 · 86 citations · Full text

Medicine, Cancer Biology, Oncology +16

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

Lisa Seitz, Lixia Jin, Manmohan R. Leleti et al. · Investigational New Drugs · 2018 · 64 citations

Medicine, Pharmacokinetics, Pharmacology +6